Marksans Pharma Limited has informed the Exchange regarding a press release dated August 07, 2023, titled "Completion of US FDA Post-marketing Adverse Drug Experience (PADE) inspection".
Marksans Pharma Limited has informed the Exchange regarding a press release dated August 07, 2023, titled "Completion of US FDA Post-marketing Adverse Drug Experience (PADE) inspection".